title: Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.
abstract: Colorectal cancer is one of the most common cancers worldwide, and associated with high mortality rates in our country. The prognosis of patients diagnosed with metastatic colorectal cancer (mCRC) has improved markedly over the last 12 years, increasing from 5 months with best supportive care to almost 2 years with combination chemotherapy plus bevacizumab. Bevacizumab is well suited for use in combination with first or second line chemotherapy in the treatment of mCRC because its side effects are predictable and appear not to add to the incidence or severity of the side effects of chemotherapy. The aim of our small study is to explore the tolerability profile of bevacizumab used in daily clinical practice in patients with metastatic colorectal cancer (mCRC) in our department.
authors.affiliation: Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Mohamed Reda
authors.initials: MR
authors.lastname: Khmamouche
authors.affiliation: Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Tarik
authors.initials: T
authors.lastname: Mahfoud
authors.affiliation: Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Aziz
authors.initials: A
authors.lastname: Bazine
authors.affiliation: Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Rachid
authors.initials: R
authors.lastname: Tanz
authors.affiliation: Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ichou
authors.affiliation: Department of Medical oncology, National institute of Oncology, Al Irfane, Hay Riad, Rabat, Morocco.
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Colorectal cancer; bevacizumab; tolerability